度洛西汀联合加巴喷丁治疗躯体形式疼痛障碍疗效分析

The effect of duloxetine enteric coated tablets combined with gabapentin capsules in of the somatoform pain disorder

目的观察度洛西汀肠溶片联合加巴喷丁胶囊治疗躯体形式疼痛障碍的临床治疗效果。方法将持续性躯体形式疼痛障碍的80例患者,随机分为研究组和对照组,分别使用度洛西汀肠溶片联合加巴喷丁胶囊和单用使用度洛西汀肠溶片进行治疗,使用视觉模拟评分(Visual Analogue Scale/Score,VAS评分)对患者治疗前以及治疗后2,4,6周的疼痛状况进行评定,并对患者的治疗效果采用使用生活质量评分(Karnofsky评分)进行评定。结果与治疗前相比,对照组和研究组治疗后2周、4周、8周VAS评分明显降低,且均具有统计学意义(P<0.05)。通过组间比较发现从治疗后第2周开始,研究组VAS评分明显低于对照组,差异具有统计学意义(P<0.05)。生活质量Karnofsky评分结果发现,两组治疗后均明显高于治疗前(P<0.05),且从治疗后第2周期,存在显著组间差异(P<0.05)。单独使用度洛西汀肠溶片有效率达到67.5%(27/40),联合用药有效率得到82.5%(33/40)。结论度洛西汀肠溶片联合加巴喷丁胶囊治疗躯体形式疼痛障碍具有良好的治疗效果,起效快,不良反应较为轻微。

Objection To investigate the effect of duloxetine enteric coated tablets combined with gabapentin capsule in the somatoform pain disorder. Methods The 80 patients, who were persistent somatoform pain disorder, were randomly divided into the study group and the control group, respectively, the use of duloxetine enteric coated tablets combined with gabapentin capsules and single charge of duloxetine enteric coated tablets for treatment, Using the Visual Analogue Scale and Karnofsky Scale, the therapeutic effect was assessed in patients in both groups before and 2, 4 and 6 weeks after treatment. Results Compared with the patients before treatment, The VAS scores of the control group and study group were significantly lower after 2 weeks, 4 weeks, 8 weeks treatment （P〈0.05） . From second weeks after treatment, the VAS score of the study group was significantly lower than that of the control group, the difference was statistically significant （P〈0.05） . Karnofsky score of quality of life found that the two groups after treatment were significantly higher than before treatment （ P〈0.05 ）, and after treatment, there were significant dif- ferences between groups （ P〈0.05 ） . The response rate of duloxetine enteric coated tablets is 67.5 % （ 27/40 ）, The response rate of combined drug is 82.5 % （ 33/40 ） . Conclusion Duloxetine combined with gabapentin capsule has a good therapeutic effect to treat somatoform pain disorder, and has low adverse reactions.